Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
Study Details
Study Description
Brief Summary
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with PD-L1 positive muscle invasive bladder carcinoma (T2-3N0M0).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
The study will enroll 20 patients with adequate organ function and performance status who either wish to attempt bladder preserving therapy or are ineligible for radical cystectomy. The bladder samples must be available and assessed as positive for PD-L1 expression . Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. After the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Gemcitabine, Cisplatin and Tislelizumab Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. 2-4 weeks after the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin. |
Drug: Tislelizumab
Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
Drug: Gemcitabine
Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
Drug: Cisplatin
Cisplatin 70mg^m2 will be administered on Day 1 for four to six 21-day cycles.
|
Outcome Measures
Primary Outcome Measures
- Two-year bladder-intact disease-free survival rate [2 years]
Bladder-intact disease-free survival is defined as time from initiation of protocol therapy until the development of muscle-invasive bladder cancer recurrence, regional pelvic recurrence, distant metastases, bladder cancer-related death, or cystectomy.
Secondary Outcome Measures
- Adverse Events [2 years]
The adverse events are evaluated per Common Terminology Criteria for Adverse Events (CTCAE) 5.
- Overall survival [up to 5 years]
Defined as time to death from beginning of protocol therapy
- Metastasis-free survival [up to 5 years]
Defined as time to the development of radiographic distant metastases from beginning of protocol therapy.
- Disease-free survival [up to 5 years]
Defined as time to recurrence, metastasis or death from beginning of protocol therapy.
- Disease specific survival [up to 5 years]
Defined as time to death because of bladder cancer from beginning of protocol therapy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed muscle-invasive urothelial cancer of the bladder within 60 days of study enrollment. Variant histology and cis are not allowed. Patients must be willing to provide a TURBT specimen during screening and prior to enrollment if adequate specimen (FFPE tissue block or 20 unstained slides) from initial TURBT documenting muscle-invasive urothelial bladder cancer is not available. The specimen must be assessed as PD-L1 positive by two pathologists using SP263 kit.
-
Clinical stage T2-T3, N0, M0 urothelial bladder cancer.
-
Deemed to not be a candidate for radical cystectomy by attending urologic oncologist or refuse radical cystectomy.
-
Willing to receive maximal transurethral resection or partial cystectomy to remove all bladder tumors
-
Be willing and able to provide written informed consent/assent for the trial.
-
Have a performance status of 0 or 2 on the Eastern Cooperative Oncology Group Performance Scale.
-
Demonstrate adequate organ function as defined below, all screening labs should be performed within 10 days of protocol enrollment.
-
Absolute neutrophil count >= 1,500 /mcL;
-
Platelets >= 100,000 /mcL;
-
Hemoglobin >= 9.0 g/dL;
-
Serum creatinine <=1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 30 mL/min as calculated by Cockcrof-Gault formulae or by 24 hour urine collection;
-
Serum total bilirubin <=1.5 x ULN or direct bilirubin <= ULN for subjects with total -bilirubin levels > 1.5 x ULN;
-
Aspartate aminotransferase and alanine aminotransferase <= 1.5 x ULN;
-
Albumin >= 2.5 mg/dL;
-
International normalized ratio or prothrombin time (PT) <= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial prothrombin time (PTT) is within therapeutic range of intended use of anticoagulants;
-
Activated Partial Thromboplastin Time (aPTT) <= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
-
Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
-
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Exclusion Criteria:
-
Has received prior radiation therapy or systemic chemotherapy for urothelial bladder cancer including neoadjuvant chemotherapy. Prior intravesical chemotherapy or intravesical immunotherapy is permissible, however, no prior intravesical therapy is permitted within 4 weeks of study enrollment; adjuvant therapy is not permitted.
-
Has received prior pelvic radiation therapy.
-
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
-
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
-
Has a known history of active TB (Bacillus Tuberculosis).
-
Hypersensitivity to tislelizumab or any of its excipients.
-
Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
-
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
-
Any prior history of invasive malignancy within the past 5 years except non-melanoma skin cancer, carcinoma in-situ, localized prostate cancer without biochemical recurrence following definitive treatment.
-
Has other active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
-
History of Guillain-Barre Syndrome or Stevens-Johnson Syndrome
-
Has known history of, or any evidence of active, non-infectious pneumonitis.
-
Has an active infection requiring systemic therapy.
-
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
-
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
-
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
-
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
-
Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
-
Has received a live vaccine within 30 days of planned start of study therapy. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai | Shanghai | China | 200127 |
Sponsors and Collaborators
- RenJi Hospital
Investigators
- Principal Investigator: Wei Xue, PhD, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TICIG